Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

K. Dane Wittrup

AddedMar 31, 2024

UpdatedMay 31, 2026

K. Dane Wittrup

K. Dane Wittrup

Board Member, Werewolf Therapeutics

Crunchbase LinkedIn

K. Dane Wittrup's Career

Werewolf Therapeutics

Werewolf Therapeutics

Watertown, WI, US

Board Member· Board

Mersana Therapeutics

Mersana Therapeutics

Cambridge, MA, US

Board Member· Board

Immunitas Therapeutics

Immunitas Therapeutics

Waltham, MA, US

Board Member· Board

Ankyra

Boston, MA, US

Board Member· Board

76Bio

New York City, NY, US

Board Member· Board

Adimab

Lebanon, NH, US

Board Member· Board

Strand Therapeutics

Strand Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

K. Dane Wittrup's Career

Werewolf Therapeutics

Werewolf Therapeutics

Public$128.2M502017Watertown, WI, US

Board Member· Board

Leadership at Werewolf Therapeutics

Patrick BaeuerleCo-Founder

Mike ShermanBoard Member

Meeta ChatterjeeBoard Member

Luke EvninBoard Member

Dan HicklinBoard Member

Similar to Werewolf Therapeutics

PanTher TherapeuticsWatertown, MA, USCancer Treatmentest. 2016PanTher TherapeuticsWatertown, MA, US · est. 2016

PanTher Therapeutics: Revolutionizing cancer care with an effective, minimal side-effect treatment platform.

Series B · $21.3M13

Window TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4

Immune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35

Palm TherapeuticsSan Diego, CA, USCancer Treatmentest. 2018Palm TherapeuticsSan Diego, CA, US · est. 2018

Revolutionizing cancer treatment with next-gen root-level therapeutics.

Angel · $991.1k7

Mersana Therapeutics

Mersana Therapeutics

Public$655.6M2282001Cambridge, MA, US

Board Member· Board

Leadership at Mersana Therapeutics

Anna ProtopapasBoard Member

Martin HuberBoard Member

Willard DereBoard Member

Dave MottBoard Member

C. Boyd ClarkeBoard Member

Immunitas Therapeutics

Immunitas Therapeutics

Series B$97M332019Waltham, MA, US

Board Member· Board

Leadership at Immunitas Therapeutics

Geeta VemuriBoard Member

Laura BrassBoard Member

Mario SuvaCo-Founder

Brian HalakBoard Member

Amanda WagnerCEO

Lucio IannoneBoard Member

Similar to Immunitas Therapeutics

Immune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35

ImmunaiNew York City, NY, USBiomarkers, Biotechest. 2018ImmunaiNew York City, NY, US · est. 2018

Immunai, a biotech firm, uses single-cell genomics and ML for high-resolution immune profiling and biomarker discovery.

Series B · $295M167

ImmunoGenesisHouston, TX, USCancer Therapiesest. 2019ImmunoGenesisHouston, TX, US · est. 2019

ImmunoGenesis: Developing science-based therapies to combat immune-resistant tumors.

Public · $28M38

INmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17

Ankyra

Series B$59.5M172019Boston, MA, US

Board Member· Board

Leadership at Ankyra

Darrell IrvineCo-Founder

Phil FerneauBoard Member

Howard KaufmanCEO

Similar to Ankyra

AnkyrBioPittsburgh, PA, USDrug DeliveryAnkyrBioPittsburgh, PA, US

Pittsburgh-based AnkyrBio, a biotech firm, commercializes proprietary anchoring system software.

Angel · $225k5

Umoja BiopharmaSeattle, WA, USCancer Therapyest. 2019Umoja BiopharmaSeattle, WA, US · est. 2019

Umoja: Innovating cancer therapy by enhancing the body's natural defense system.

Series B · $263M203

Pionyr ImmunotherapeuticsSan Francisco, CA, USCancer Immunotherapyest. 2015Pionyr ImmunotherapeuticsSan Francisco, CA, US · est. 2015

Pionyr Immunotherapeutics: Advancing cancer immunotherapies to enhance the body's antitumor response.

Late Stage Private · $352M175

Avenge BioNatick, MA, USImmunotherapiesest. 2019Avenge BioNatick, MA, US · est. 2019

Avenge Bio: Developing transformative therapeutics to potentially eradicate solid tumors.

Series A · $45M23

76Bio

Series A$10M162020New York City, NY, US

Board Member· Board

Leadership at 76Bio

Marius PopCo-Founder

Angela KoehlerCo-Founder

Chris WilfongCo-Founder

Similar to 76Bio

BiotheryxSan Diego, CA, USBiopharmaceuticalsest. 2007BiotheryxSan Diego, CA, US · est. 2007

US-based BioTheryX: Developing therapies for hematological malignancies.

Public · $134.7M39

EpiBiologicsSan Mateo, CA, USTargeted Therapiesest. 2022EpiBiologicsSan Mateo, CA, US · est. 2022

EpiBiologics: Pioneering antibody-based therapies targeting disease-driving proteins.

Series A · $73M38

NeomorphSan Diego, CA, USDrug Discoveryest. 2020NeomorphSan Diego, CA, US · est. 2020

Neomorph, a San Diego-based biotech firm, innovates new medicines to solve critical health issues.

Series A · $109M62

Origami Therapeutics, Inc.San Diego, CA, USProtein Degradersest. 2015Origami Therapeutics, Inc.San Diego, CA, US · est. 2015

Developing drugs to degrade toxic proteins for neurodegenerative diseases.

Pre-Seed · $500k4

Adimab

Public$45.5M1492007Lebanon, NH, US

Board Member· Board

Leadership at Adimab

Fran HellerBoard Member

Tillman GerngrossBoard Member

Carl L. GordonBoard Member

Terry McguireBoard Member

Philip ChaseBoard Member

Bill MarisBoard Member

Strand Therapeutics

Strand Therapeutics

Series A$104.2M1272017Cambridge, MA, US

Board Member· Board

Recent news

New York tech investor and serial entrepreneur Kevin Ryan explains when to sell your companyTechCrunch · 2024

Leadership at Strand Therapeutics

Jacob BecraftCo-Founder

Tasuku KitadaBoard Member

Ron WeissCo-Founder

K. Dane Wittrup's Similar Executives & Operators

Nugroho HerucahyonoCo-Founder · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Lau Eng BoonBoard Member · Bukalapak

Achmad ZakyCo-Founder · Bukalapak

Jay Geoffrey WacherBoard Member · Bukalapak

WILL WEI CHENGBoard Member · DiDi

Bo ZhangCo-Founder · DiDi

Dhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to K. Dane Wittrup

John SwansonFounder · Ansys

John CioffiBoard Member · Assia

William Boyce ThompsonFounder · Newmont

Eugene KleinerCo-Founder · Kleiner Perkins Caufield & Byers

Vikram Sheel KumarCo-Founder · Dimagi

Jim FruchtermanFounder · Tech Matters